Repurposing the FDA‐approved anticancer agent ponatinib as a fluconazole potentiator by suppression of multidrug efflux and Pma1 expression in a broad spectrum of yeast species

Repurposing the FDA‐approved anticancer agent ponatinib as a fluconazole potentiator by suppression of multidrug efflux and Pma1 expression in a broad spectrum of yeast species

Summary Fungal infections have emerged as a major global threat to human health because of the increasing incidence and mortality rates every year. The emergence of drug resistance and limited arsenal of antifungal agents further aggravates the current situation resulting in a growing challenge in m...

Full description

Bibliographic Details
Main Authors: Lin Liu, Tong Jiang, Jia Zhou, Yikun Mei, Jinyang Li, Jingcong Tan, Luqi Wei, Jingquan Li, Yibing Peng, Changbin Chen, Ning‐Ning Liu, Hui Wang
Format: Article
Language:English
Published: Wiley 2022-02-01
Series:Microbial Biotechnology
Online Access:https://doi.org/10.1111/1751-7915.13814

Similar Items

Similar Items